Clinical Trial Update: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of VTX-2337 in combination with radiotherapy for low-grade B-cell lymphoma was terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Lymphoma

Drugs mentioned

• VTX-2337 (TLR8 agonist)

Snippet

Sponsor: Celgene | Conditions: Low Grade B Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-10-06